Sanofi vWD therapy demonstrates significant potential of pipeline

French pharma major Sanofi (Euronext: SAN) has successfully completed the Phase I trial for its von Willebrand disease (vWD) therapy, efanesoctocog alfa (BIV001), a novel antihemophilic factor recombinant fusion protein that acts as a coagulation factor VIII therapy.

This is a significant potential addition to the future of the late stage vWD pipeline, which currently lacks novel molecules and therapies that can address severe vWD, says data and analytics company GlobalData.

The US Food and Drug Administration (FDA) earlier this year approved the Biologics License Application (BLA) for Altuviiio (efanesoctocog alfa) for the treatment of hemophilia A, a rare and life-threatening bleeding disorder.